The AMR Action Fund announced that one of its portfolio companies, UTILITY Therapeutics, Ltd., received approval from the U.S. Food and Drug Administration (FDA) for the antibiotic PIVYA™ (pivmecillinam) for the treatment of uncomplicated UTIs (uUTI).

Your front page story “Japan wrestles with age-old problem as population declines at record rate” (Report, April 13) and the letter in the same edition from Tim Hill, “A gently declining population is no reason to panic”, both describe what all societies face as they modernise in the 21st century. It’s a topic Japan’s Prime…

New research examines employers’ workforce management priorities, business practices, and benefit offerings LOS ANGELES – March 27, 2024 – Almost seven in 10 employers (69%) either currently use or plan to use robotics or artificial intelligence to augment their human workforce, according to a new survey by nonprofit Transamerica Institute® and its Transamerica Center for…

A recent appeals court ruling in California has posed a burning question for regulators, the life sciences industry, and patients. Who should be in charge of developing safe, life-saving medications: scientific experts and the FDA, or judges?   There’s a troubling answer — and disastrous implications — in the ruling, which, if it stands, would…

How companies are adapting to aging populations around the world with new products, new personnel policies and new marketing tactics.      On the one hand, the declining birthrate and the shrinking population of working age people in many countries present challenges to finding sufficient manpower to staff factories and offices to meet existing demand. Companies…